Biological significance of agmatine, an endogenous ligand at imidazoline binding sites

British Journal of Pharmacology

Volumn 133, Issue 6, 2001, Pages 755-780

  Raasch, W ^a   Schafer U ^a   Chun, J ^a   Dominiak, P ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Agmatine; Blood pressure; CDS; Gastric acid; Growth effects; Imidazoline binding site; Insulin secretion; Neuroprotection; Renal effects

Indexed keywords

AGMATINE; BRIMONIDINE; CLONIDINE; CLONIDINE DISPLACING SUBSTANCE; IMIDAZOLINE; LIGAND;

BINDING SITE; BIOSYNTHESIS; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG INACTIVATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; PRIORITY JOURNAL; REVIEW;

EID: 0034890832     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704153     Document Type: Review

References (291)

1. The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment
2. Mechanism of action of the monoguanidine hypoglaemic agents, galegine and agmatine
3. LSL 60101, a selective ligand for imidazoline 12 receptors, on glial fibrillary acidic protein concentration
4. Renal imidazoline preferring sites and solute excretion in the rat
5. Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine
6. Abnormal regulation of the sympathetic nervous system in alpha2A- adrenergic receptor knockout mice
7. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats
8. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha 2-adrenergic receptor activity
9. Identifying clonidine-displacing substance
10. Molecular and physiological properties of clonidine-displacing substance
11. Isolation and partial purification of a clonidine-displacing endogenous brain substance
12. Isolation of an endogenous clonidine-displacing substance from rat brain
13. The brain's own clonidine: Purification and characterization of endogenous clonidine displacing substance from brain
14. Selective inhibition of inducible nitric oxide synthase by agmatine
15. Effects of imidazolines and derivatives on insulin secretion and vascular resistance in perfused rat pancreas
16. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed
17. Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine
18. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat
19. Dual action of clonidine on ethanol-induced gastric lesions: Is the imidazoline-preferring receptor involved?
20. Video microscopy of intracellular pH in primary cultures of rabbit proximal and early distal tubules
21. Metabolism of L-arginine through polyamine and nitric oxide synthase pathways in proliferative or differentiated human colon carcinoma cells
22. Alpha 2-adrenoceptor-mediated inhibitory and excitatory effects of detomidine on rat gastric acid secretion
23. Modulation of gastric acid secretion by peripheral presynaptic alpha 2- adrenoceptors at both sympathetic and parasympathetic pathways
24. Characterization of alpha 2-adrenoceptor subtypes involved in the modulation of gastric acid secretion
25. The natural history of amine oxidases
26. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine
27. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other 12-imidazoline ligands
28. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure
29. Central cardiovascular effects of a noncatecholamine endogenous ligand for clonidine receptors
30. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines
31. Effect of agmatine on spinal nociceptive reflexes: Lack of interaction with alpha2-adrenoceptor or mu-opioid receptor mechanisms
32. The imidazoline preferring receptor: Binding studies in bovine, rat and human brainstem
33. Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem
34. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080
35. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites
36. Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain
37. Role of medullary II-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats
38. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites
39. Clonidine-displacing substance and its putative role in control of insulin secretion: A minireview
40. The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans
41. The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1- and I2-sites
42. Pancreatic beta-cells express an imidazoline binding site that is distinct from I1 and I2 sites
43. The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells
44. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels
45. Pharmacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA antagonists
46. Effects of imidazoline derivatives on cholinergic motility in guinea-pig ileum: Involvement of presynaptic alpha2-adrenoceptors or imidazoline receptors?
47. Imidazoline-guanidinium receptive site in renal proximal tubule: Asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance
48. Helicobacter pylori infection: Physiopathologic implication of N alpha-methyl histamine
49. The classification of adrenoceptors and their effects on gastric acid secretion
50. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system
51. Autoradiographic distribution of alpha 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine
52. Protection by imidazol(ine) compounds of L-glutamate neurotoxicity through NMDA receptor blockade
53. Pharmacological studies on the mechanisms underlying the inhibitory and excitatory effects of clonidine on gastric acid secretion
54. The effect of pirenzepine on gastric acid secretion and gastrin release induced by bombesin and meal in the dog
55. An endogenous brain substance, CDS (clonidine-displacing-substance), inhibits the twitch response of rat vas deferens
56. Interrelationships between increased vascular permeability and acute neuronal damage following temperature-controlled brain ischemia in rats
57. Production and characterization of anti-clonidine antibodies not cross-reacting with catecholamines
58. Transport of diamines by Enterococcus faecalis is mediated by an agmatineputrescine antiporter
59. Potassium channels, imidazolines, and insulin-secreting cells
60. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
61. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development
62. The I1-imidazoline receptor and its cellular signaling pathways
63. Characterization and visualization of clonidine-sensitive imidazole sites in rat kidney which recognize clonidine-displacing substance
64. Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla
65. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla
66. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling
67. A novel mechanism of action for hypertension control: Moxonidine as a selective I1-imidazoline agonist
68. Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla
69. An endogenous substance with clonidine-like properties: Selective binding to imidazole sites in the ventrolateral medulla
70. 1-imidazoline receptors
71. Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: Relationship with non-adrenoceptor [3H]-idazoxan binding sites
72. Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods
73. Alpha 2 adrenoceptor- and imidazoline-prefering binding sites in the dog kidney
74. Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice
75. Clonidine displacing substance is biologically active on smooth muscle
76. Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection
77. Evidence for a central alpha-sympathomimetic action of clonidine in the rat
78. Über eine synthetische substanz (synthalin) mit insulinartiger wirkung
79. Desensitization of inhibitory prejunctional alpha 2-adrenoceptors and putative imidazoline receptors on rabbit heart sympathetic nerves
80. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine
81. Agmatine: A novel endogenous vasodilator substance
82. Platelet imidazoline receptors and regulatory G proteins in patients with major depression
83. Imidazoline receptors and human brain disorders
84. Density of imidazoline receptors in platelets of euthymic patients with bipolar affective disorder and in brains of lithium-treated rats
85. Imidazoline receptor proteins in brains of patients with Alzheimer's disease
86. Arginine and ornithine decarboxylation in rodent brain: Coincidental changes during development and after ischemia
87. Agmatine treatment is neuroprotective in rodent brain injury models
88. Metabolism of agmatine into urea but not into nitric oxide in rat brain
89. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats
90. Moxonidine decreases gastric secretion and gastric mucosal injury in rats
91. Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats
92. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area
93. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery
94. Clonidine and the treatment of the opiate withdrawal syndrome
95. Presynaptic imidazoline receptors. New developments in characterization and classification
96. Involvement of presynaptic imidazoline receptors in the alpha 2- adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives
97. Alpha 2-adrenoceptor-independent inhibition by imidazolines and guanidines of noradrenaline release from peripheral, but not central noradrenergic neurons
98. Isolation and partial structure determination of a clonidine-displacing substance from bovine lung and brain
99. Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: Influence of time of administration and possible mechanisms of action
100. Effects of agmatine on catecholamine release and blood pressure of spontaneously hypertensive rats. A possible role for imidazoline receptors?
101. Influence of imidazolines on catecholamine release in pithed spontaneously hypertensive rats
102. Proceedings: Sympathetic nerve activity after noradrenaline depletion and its alteration by clonidine
103. Clonidine-induced inhibition of sympathetic nerve activity: No indication for a central presynaptic or an indirect sympathomimetic mode of action
104. Plasma agmatine and platelet imidazoline receptors in depression
105. Increased imidazoline and alpha 2 adrenergic binding in platelets of women with dysphoric premenstrual syndromes
106. Adrenergic and nonadrenergic effects of imidazoline and related antihypertensive drugs in the brain and periphery
107. The role of imidazoline receptors in blood pressure regulation
108. Do centrally-acting antihypertensive drugs act at non-adrenergic as well as alpha-2 adrenoceptor sites?
109. Selective antihypertensive action of moxonidine is mediated mainly by II-imidazoline receptors in the rostral ventrolateral medulla
110. Central cardiovascular actions of agmatine, a putative clonidine-displacing substance, in conscious rabbits
111. Transgenic models of alpha 2-adrenergic receptor subtype function
112. Gene substitution/knockout to delineate the role of alpha 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines
113. Clonidine-displacing substance is present in peripheral tissues of the rat
114. Selective alpha-2 adrenoceptor blockade by SK&F 86466: In vitro characterization of receptor selectivity
115. Imidazoline receptors: Historical perspective
116. Effects of alpha-adrenoceptor agonists and antagonists on insulin secreting cells and pancreatic blood vessels: Comparative study
117. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors
118. Effect of intrathecal agmatine on inflammation-induced thermal hyperalgesia in rats
119. Effects of histamine H2 receptor antagonists on acid secretion stimulated by imidazoline derivatives in isolated parietal cells
120. Inhibition of polyamine biosynthesis in Crithidia fasciculata by D,L-alpha-diftuoromethylornithine and D,L-alpha-difluoromethylarginine
121. Block of pancreatic ATP-sensitive K + channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline
122. N omega-hydroxyagmatine: A novel substance causing endothelium- dependent vasorelaxation
123. Imidazoline antagonists of alpha 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic beta-cells
124. The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat
125. Functional properties of agmatine in rat vas deferens
126. Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain
127. Apparently unidirectional polyamine transport by proton motive force in polyaminc-deficient Escherichia coli
128. Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine
129. Centrally induced reduction in sympathetic tone-a postsynaptic alpha- adrenoceptor-stimulating action of imidazolines
130. Modulation of opioid analgesia by agmatine
131. Über das Agmatin
132. Antidepressant-like effects of endogenous histamine and of two histamine H1 receptor agonists in the mouse forced swim test
133. Effects of alpha-adrenoceptor antagonists on clonidine-induced inhibition of insulin secretion by isolated pancreatic islets
134. Alpha-adrenoreceptor subtypes in blood vessels: Physiology and pharmacology
135. The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo
136. Agmatine: An endogenous clonidine-displacing substance in the brain
137. Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain
138. Attenuated renal response to moxonidine and rilmenidine in one kidney- one clip hypertensive rats
139. Presynaptie imidazoline receptors and alpha 2-adrenoceptors in the human heart: Discrimination by clonidine and moxonidine
140. Purification and characterization of mitochondrial imidazoline-guanidtnium receptive site from rabbit kidney
141. Involvement of alpha-2 adrenoceptors in the effects of moxonidine on intestinal motility and fluid transport
142. Agmatine acts as an antagonist of neuronal nicotinic receptors
143. Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat
144. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Pharmacological characterization
145. Central hypotensive effects of the alpha2a-adrenergic receptor subtype
146. Reduction in focal cerebral ischemia by agents acting at imidazole receptors
147. Characterization and autoradiographical localization of non- adrenoceptor idazoxan binding sites in the rat brain
148. Clonidine and other alpha2 adrenergic agonists: Strategies for the rational use of these novel anesthetic agents
149. Effects of clonidine, guanfacine and three imidazolidine derivatives related to clonidine on blood pressure, heart rate and gastric acid secretion in the anaesthetized rat
150. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla
151. Clonidine-specific anti-bodies as models for imidazole and alpha 2-adrenergic receptor binding sites: Implications for the structure of clonidine-displacing substance
152. Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum
153. A specific anti-serum recognizes clonidine-displacing substance: Implications for the structure of the brain's own clonidine
154. Catabolism of L-arginine by Pseudomonas aeruginosa
155. Astrocytes play a role in regulation of synaptic density
156. [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site
157. Keeping an eye on the I site: Imidazoline-preferring receptors
158. Are there multiple imidazoline binding sites?
159. alpha-Adrenergic regulation of human renal function
160. Agmatine and putrescine uptake in the human glioma cell line SK-MG-1
161. Potential relevance of agmatine as a virulence factor of Helicobacter pylori
162. Imidazoline recognition sites and stomach function
163. Characterization of 12 imidazoline and sigma binding sites in the rat and human stomach
164. Characterization of non-adrenergic [3H]clonidine binding sites in rat stomach: High affinity of imidazolines, guanidines and sigma ligands
165. Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from II- and 12-imidazoline binding sites
166. Potential relevance of agmatine for the pathogenesis of gastric mucosal lesions
167. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery
168. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship
169. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues
170. Imidazoline derivatives and agmatine induce histamine release from the rat stomach
171. Dual interaction of agmatine with the rat alpha(2D)-adrenoceptor: Competitive antagonism and allosteric activation
172. Binding of [3H]clonidine to II-imidazoline sites in bovine adrenal medullary membranes
173. Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: Potential involvement of sigma 2 binding sites
174. Characterization of the imidazoline binding site involved in regulation of insulin secretion
175. Imidazolines and pancreatic hormone secretion
176. Synthesis and pharmacologic evaluation of 2-endo-amino-3-exoisopropylbicyclo [2.2.1]heptane: A potent imidazoline I receptor specific agent
177. Molecular mechanisms of drug addiction: Adaptations in signal transduction pathways
178. The distribution and significance of CNS adrenoceptors examined with in situ hybridization
179. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: An in situ hybridization study
180. Effects of imidazole compounds on catecholamine release in adrenal chromaffin cells
181. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain
182. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor
183. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain
184. Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain
185. Regional localization of agmatine in the rat brain: An immunocytochemical study
186. Biosynthesis of polyamines in ornithine decarboxylase, arginine decarboxylase, and agmatine ureohydrolase deletion mutants of Escherichia coli strain K-12
187. Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues
188. Comparison of crude methanolic CDS extracts from various tissues
189. Polyamine metabolism and function
190. Natriuresis following central and peripheral administration of agmatine in the rat
191. Translational regulation of ornithine decarboxylase by polyamines
192. Gastrin and acid in relation to Helicobacter pylori
193. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors
194. Involvement of II-imidazoline receptors in mood disorders
195. Platelet II-imidazoline binding sites are elevated in depression but not generalized anxiety disorder
196. Platelet II-imidazoline binding sites are decreased by two dissimilar anti-depressant agents in depressed patients
197. Imidazoline receptor anti-sera-selected (IRAS) cDNA: Cloning and characterization
198. Comparison of ligand binding affinities at human II-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes
199. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites
200. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors
201. Phentolamine and yohimbine inhibit ATP-sensitive K+ channels in mouse pancreatic beta-cells
202. Histamine release from mast cells by polyamines: An NMDA receptor- mediated event?
203. Clonidine in pain management
204. Inhibition of nicotinic receptor mediated ion fluxes in rat sympathetic ganglia by BGT II-S1 a potent phospholipase
205. Positive inotropic effects of imidazoline derivatives are not mediated via imidazoline binding sites but alpha 1-adrenergic receptors
206. 2-adrenoceptors but also through imidazoline binding sites
207. 2 specific ligands in vitro
208. Modulation of MAO activity by imidazoline and guanidine derivatives
209. Agmatine, the bacterial amine, is widely distributed in mammalian tissues
210. Agmatine is widely and unequally distributed in rat organs
211. Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B
212. Imidazoline/guanidinium binding domains on monoamine oxidases, Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B
213. Localization of the imidazoline binding domain on monoamine oxidase B
214. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme
215. Imidazoline binding domains on MAO-B. Localization and accessibility
216. Arginine decarboxylase from Lathyrus sativus seedlings. Purification and properites
217. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells
218. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes
219. Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved?
220. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells
221. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal medulla
222. Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells
223. Characterization of arginine decarboxylase in rat brain and liver: Distinction from ornithine decarboxylase
224. Agmatine is released from synaptosomes and adrenal chromaffin cells by depolarization
225. Imidazoline receptors and agmatine in blood vessels: A novel system inhibiting vascular smooth muscle proliferation
226. Imidazoline receptors in vascular smooth muscle and endothelial cells
227. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol
228. Agmatine: A novel neurotransmitter?
229. Identifying clonidine-displacing substance
230. Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion
231. The CI area of the rostral ventrolateral medulla oblongata. A critical brainstem region for control of resting and reflex integration of arterial pressure
232. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells
233. Analysis of the pharmacological and molecular heterogeneity of I(2)- imidazoline-binding proteins using monoamine oxidase-deficient mouse models
234. Lack of cross-desensitization between structurally dissimilar alpha-adrenoceptor agonists
235. Distribution of imidazoline receptor binding protein in the central nervous system
236. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells
237. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: A model to detect agonist and antagonist activities at these receptors
238. Lateral hypothalamic innervation of the cerebral cortex: Immunoreactive staining for a peptide resembling but immunochemically distinct front pituitary /arcuate alpha-melanocyte stimulating hormone
239. Decreased number and immunoreactivity of 12-imidazoline receptors in the frontal cortex of suicide victims
240. Metabolism of agmatine in macrophages: Modulation by lipopolysaccharide and inhibitory cytokines
241. Agmatinase activity in rat brain: A metabolic pathway for the degradation of agmatine
242. Uptake of agmatine into rat brain synaptosomes: Possible role of cation channels
243. Decreased density of 12-imidazoline receptors in the postmortem brain of heroin addicts
244. Purification and properties of agmatine ureohydrolyase, a putrescine biosynthetic enzyme in Escherichia coli
245. Agmatine suppresses proliferation by frameshift induction of anti-zyme and attenuation of cellular polyamine levels
246. The cardiovascular effects of agmatine are not mediated via peripheral binding sites but via blockade of the ganglionic transmission
247. Effects of agmatine on the cardiovascular system
248. Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats
249. Dual action of clonidine on insulin release: Suppression, but stimulation when alpha 2-adrenoceptors are blocked
250. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors
251. Agmatine affects glomerular filtration via a nitric oxide synthase- dependent mechanism
252. Polyamine transport in mammalian cells
253. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine
254. Evidence for the presence of a non-catecholamine, clonidine-displacing substance in crude, methanolic extracts of bovine brain and lung
255. Role of polyamines in the regulation of proliferation and hormone production by insulin-secreting cells
256. Selective alpha 2-adrenoceptor activation by clonidine: Effects on 45Ca2 + efflux and insulin secretion from isolated rat islets
257. Renal II-imidazoline receptor-selective compounds mediate natriuresis in the rat
258. Peripheral and central imidazoline receptor-mediated natriuresis in the rat
259. Helicobacter pylori stimulates gastric acid secretion via platelet activating factor
260. Signal transduction and regulation in smooth muscle
261. Significance of imidazolines for catecholamine release and for voltage-gated calcium channels in the bovine chromaffin cell
262. Quantitation of the putative neurotransmitter agmatine as the hexafluoroacetylacetonate derivative by stable isotope dilution gas chromatography and negative-ion chemical ionization mass spectrometry
263. Morphine alters astrocyte growth in primary cultures of mouse glial cells: Evidence for a direct effect of opiates on neural maturation
264. Morphine suppresses DNA synthesis in cultured murine astrocytes from cortex, hippocampus and striatum
265. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat
266. Human plasma-derived material with clonidine displacing substance (CDS)- like properties contracts the isolated rat aorta
267. Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits
268. Polyamines
269. Localization of 12-imidazoline binding sites on monoamine oxidases
270. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites
271. Identification of an imidazoline-guanidinium receptive site in mitochondria front rabbit cerebral cortex
272. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane
273. The complete genome sequence of the gastric pathogen Helicobacter pylori
274. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence
275. The imidazoline II receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans
276. 12-Imidazoline receptors in platelets of patients with Parkinson's disease and Alzheimer's type dementia
277. Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway
278. Agmatine modulates polyamine content in hepatocytes by inducing spermidine/spermine acetyltransferase
279. An anti-serum to idazoxan recognizes an immunoreactive substance in human serum and cerebral spinal fluid which is not agmatine
280. An anti-body to agmatine localizes the amine in bovine adrenal chromaffin cells
281. Metabolic effects of arginine derivatives. I. Insulin like activity of arginyl compounds in vitro
282. Metabolic effects of arginine derivatives. 2. Antilipolytic action of arginyl compounds
283. Metabolic effects of arginine derivatives. 3. Insulin-like activity of L-arginine-N,N-dialkylamides in vitro
284. Prostaglandin-mediated inhibition of noradrenaline release: Its resistance to variations in rate of prostaglandine synthesis
285. Activities and properties of putrescine-biosynthetic enzymes in Vibrio parahaemolyticus
286. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons
287. NG-hydroxy-L-arginine and hydroxyguanidine potentiate the biological activity of endothelium-derived relaxing factor released from the rabbit aorta
288. Nitric oxide and another potent vasodilator are formed from NG-hydroxy- L-arginine by cultured endothelial cells
289. Mechanisms of the endothelium-dependent relaxation induced by NG-hydroxy-L-arginine
290. Potentiation of the vasorelaxant activity of nitric oxide by hydroxyguanidine: Implications for the nature of endothelium-derived relaxing factor
291. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice